Calcitonin gene-related peptide type 1 receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Calcitonin gene-related peptide type 1 receptor shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q16602. Start with migraine disorder, then reuse UniProt Q16602 as the stable protein anchor across project notes and exports.
Start with migraine disorder, then reuse UniProt Q16602 as the stable protein anchor across project notes and exports.
Calcitonin gene-related peptide type 1 receptor shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 10 linked drugs remain visible in the same block.
Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ATOGEPANT, BI-44370, ERENUMAB, MK3207. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCalcitonin gene-related peptide type 1 receptor
Review this target as Calcitonin gene-related peptide type 1 receptor, mapped to UniProt Q16602. Sequence length is 461 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Calcitonin gene-related peptide type 1 receptor as ChEMBL target CHEMBL3798, mapped to UniProt Q16602. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Calcitonin gene-related peptide type 1 receptor is the right protein anchor across sources, using UniProt Q16602 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why migraine disorder is currently framed as approved-linked support. It currently carries 10 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Calcitonin gene-related peptide type 1 receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q16602 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Calcitonin gene-related peptide type 1 receptor |
| UniProt Accession | Q16602 |
| Component Type | Protein |
| Sequence Length | 461 aa |
Calcitonin gene-related peptide type 1 receptor
Review this target as Calcitonin gene-related peptide type 1 receptor, mapped to UniProt Q16602. Sequence length is 461 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Calcitonin gene-related peptide type 1 receptor shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block.
Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ATOGEPANT, BI-44370, ERENUMAB, MK3207. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL207197 | 11.0 | Ki | 0.01 | Clinical |
| CHEMBL454791 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL6015508 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5978732 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5865405 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5810695 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL5755575 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL452966 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL2336422 | 10.96 | Ki | 0.011 | Preclinical |
| CHEMBL508453 | 10.96 | IC50 | 0.011 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 47 | 192 | 8.0 |
| cell-based format | 35 | 420 | 8.2 |
| assay format | 10 | 207 | 8.8 |
| cell membrane format | 6 | 9 | 8.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 47 | 376 | 7.8 |
| assay format | 3 | 47 | 6.7 |